Nexus Pharmaceuticals Launches Fluorescein 2 mL
Nexus Pharmaceuticals, LLC is expanding their Fluorescein dosage options to include Fluorescein Injection, USP 25% in a 2 mL vial alongside Fluorescein Injection, USP 10% in a 5 mL vial. Nexus is committed to enhancing the availability of Fluorescein across the optometry market.
Nexus Pharmaceuticals Launches Tranexamic Acid
Nexus Pharmaceuticals, LLC announced the launch of Tranexamic Acid. This milestone is another step for Nexus in its mission to provide life-saving medication to those who need it most.
Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection
Nexus Pharmaceuticals, LLC announces the U.S Food and Drug Administration (FDA) approval of Tacrolimus Injection 5 mg/mL. Nexus’ Tacrolimus Injection is the first and only vial that will be available.
Nexus Pharmaceuticals Receives FDA Approval for Methylene Blue Injection, USP
Nexus Pharmaceuticals, LLC announces the U.S. Food and Drug Administration (FDA) approval of Methylene Blue Injection, USP. Methylene Blue is an oxidation-reduction agent that offers treatment of acquired methemoglobinemia.
Nexus Pharmaceuticals Launches Baclofen Injection, USP
Today, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP. This sterile solution is designed for intrathecal administration and serves as a muscle relaxant and antispastic. Baclofen Injection is often used to treat patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms.
Nexus Pharmaceuticals Receives FDA Approval for Fluorescein Injection, USP
Nexus Pharmaceuticals, LLC announced it has received U.S. Food and Drug Administration (FDA) approval for Fluorescein Injection, USP.
